



Newsletter

CREATE Health - a Strategic Centre for Translational Cancer Research at Lund University November- 2012

IVA Gold Medal to Carl Borrebaeck

Carl Borrebaeck has been awarded the Royal Swedish Academy of Engineering Sciences, IVA, Gold Medal.

The justification is "his fundamental and pioneering research in applied immunology" and "his great entrepreneurship."

Carl received his medal on Friday, 28th of October at the Stockholm Concert Hall, from the Majesty King Carl XVI Gustaf during IVA's 93rd Celebration Gathering.



In addition Carl was recently awarded the prestigious Forska! Sverige-award 2012. He received the award for his pioneering research in medicine and for his great entrepreneurship.

KAW Grant to Thomas Laurell

CREATE Health's Thomas Laurell has recently received 33 million SEK from the Knut and Alice Wallenberg Foundation to develop the ultrasound-based microchip technology - acoustophoresis. The method can be used to detect cancer cells in a blood sample and also to study cell interactions with drugs. In the first step, the focus will be on prostate cancer but the method is also adapted for other types of cancers.



- The timing is fantastic! We are in a position where we are ready to start testing clinical samples, a step that requires a lot of resources, says Thomas Laurell. If clinical evaluations are positive, a new method to quantify tumor cells in the blood will be available in the care in five to ten years.

CREATE Health on Medicon Village

A year ago, Lund University was given the opportunity to take over parts of AstraZeneca's site in Lund. This was made possible through a generous donation from the famous entrepreneur Mats Paulsson. The facilities are well suited for the activities needed for cancer research and there is now an ongoing process to create a new LU Cancer Center. A couple of hundred cancer scientists from the Faculties of Engineering, Medicine and Science will start to move in during the first quarter of 2013. The organizations of CREATE Health and BioCARE will move into the northernmost building, and will make up a significant parts of this new organization. Another important

part of the work to create a new cancer center has been to plan the facilities to encourage cooperation across faculty borders. This includes of both strategic planning of where the different research groups should be localized, but also which heavy equipment can be made available and where to best place it. The cancer center will be interdisciplinary and function across faculty borders to facilitate for scientists to interact and cooperate to solve problems associated with complex diseases. We are aiming at having 2-300 cancer scientists from Lund University present at Medicon Village during 2013, which will pave the way for the creation of one of the best cancer centers in Europe. For most recent news register to the newsletter at www.lu.se/mediconvillage

SCAN-B

The South Sweden Cancerome Analysis Network – Breast initiative (SCAN-B) have implemented routine gene expression and genomic tumor profiling in the clinical setting of breast cancer, including all new breast cancer cases in southern Sweden. SCAN-B provide novel clinical tools for a more refined, individualized, and optimized medical decision-making process, including diagnostic tests for tumor classification, prognosis and treatment response. SCAN-B patient recruitment and sampling started in November 2010, and by July 2012 more than 1900 tumour/blood samples have been collected. A retrospective series of >500 frozen breast tumour/blood samples have also been processed for DNA, RNA and protein isolation, and FFPE sections from this retrospective series have been re-stained and scored for histological grade, HER2, ER, PR and Ki67 by several independent pathologists, providing a basis for development of new markers. We anticipate 1500-2000 samples to be run within the coming 12-18 months, and then continuously on new diagnosed cases, >1000 annually, and ~5000 collectively by 2014, says Åke Borg. SCAN-B aims to build knowledge and confidence in the genomics technology and facilitate clinical trials and interactions with the pharma industry. This will be accomplished by a network of scientist at CREATE Health, SCIBLU Genomics and Dept of Oncology in Lund, together with a panel of physicians and the cancer registry in South Sweden.

CREATE Health in China

In May 2012 CREATE Health was part of a delegation trip, arranged by Region Skåne, that visited university hospitals within the cancer area in Beijing, Tianjin and Shanghai. We met several research groups, conducting very interesting research, who were interested in further collaboration.



The contacts have now been followed up and the discussion concerning collaborative projects will continue during a new visit in November when necessary agreements also will be signed.

Skånska Dagbladet wrote an article about our collaboration: Visit www.createhealth.lth.se/fileadmin/create_health/pdf/120916_Skanskan_on_Kina.pdf or scan the QR-code

Cutting Edge Projects

In 2012 CREATE Health launched a new initiative called the Cutting Edge Projects (CE-projects). The aim of the CE-project is to increase cooperation within the center and to bring forward new and innovative projects that are not implemented in the framework of regular research grants.

All researchers within CREATE Health can propose projects and representatives from the Board will act as evaluators.

A CE-projects will be evaluated after one year, and funding may be extended for an additional year.

The 2012/13 Cutting Edge Projects are:

- **Detection of Cancer Cells in Sentinel Nodes**
Project leader: Peter James
- **Comprehensive platform and software development for protein arrays**
Project leader: Patrik Edén
- **EPO receptors in breast cancer**
Project leader: Sven Pålman
- **Multiplexed immunoassays in solution - novel opportunities for high-throughput disease proteomics**
Project leader: Christer Wingren

Call for new projects will be out during spring 2013

Cancer Crosslink Sweden

On October 11, CREATE Health, together with Bristol Myers Squibb, MSD and Roche, arranged the first Cancer Crosslink conference in



Sweden. Among the speakers you found Dr Edward Abrahams, Personalized Medicine Coalition and Prof. Jonathan Knowles, FIMM.

The focus on the conference was Personalized Medicine and we were bringing together researchers from healthcare providers, academia, and industry with representatives from regulatory bodies to start an interdisciplinary discussion that could lead to new partnerships to develop the area of Personalized Medicine. We are very happy with the result. Over 150 researchers attended the conference and we had many stimulation discussions.

The concept of Cancer Crosslink meetings was established in Oslo, Norway, five years ago when Oslo Cancer Cluster in collaboration with Bristol-Myers Squibb arranged the first Cancer Crosslink meeting. Since then, initiatives to Crosslink meetings has been taken both in Finland and Sweden

Oslo Cancer Cluster is arranging a Cancer Crosslink meeting at the new Radium Hospital Research Building in Oslo at January 17, 2013. This year's theme will be Personalized Medicine with special focus on Targeted Therapy. Read more at: <http://www.oslocancercluster.no/tab-id/68/Default.aspx?EventID=120&EventOccurrenceID=131>



Regional Cancer Cluster - South

Professor Mef Nilbert was recently appointed head of the Regional Cancer Centre South (RCC South). Mef Nilbert succeeds Professor Carsten Rose, CREATE Health, who was one of the initiators of the RCC South. In her role as head of the RCC Mef is responsible for implementing the proposals from the national cancer strategy to reduce the risk of developing cancer, improve the care of cancer patients, prolong survival, improve quality of life after diagnosis and to reduce regional differences in incidence and survival between populations.



New Publications

Belinda Adler et al. Optimizing Nanovial Outlet Designs for Improved Solid-Phase Extraction in the Integrated Selective Enrichment Target - ISET, Electrophoresis, 2012, on-line

Fredlund E et al. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res. 2012;14(4):R113

Jönsson G et al. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer. Cancer Res. 2012;72(16):4028-36

Holm K et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012 Jun 20.

Nik-Zainal S et al. The life history of 21 breast cancers. Cell. 2012;149(5):994-100

Nik-Zainal S et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149(5):979-993

Sandström A et al. Serum proteome profiling of pancreatitis using recombinant antibody microarrays reveals disease-associated biomarker signatures. Proteomics - Clin Appl

Wingren C et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 2012 72, 2481-2490

Pamphlet

Download the CREATE Health Pamphlet at http://www.createhealth.lth.se/fileadmin/create_health/pdf/CREATE_Health_2011.pdf or send a mail to Ulrika. Ringdahl@immun.lth.se for a hard copy.



CREATE Health on

You can now follow our activities on Facebook. We publish news, information regarding interesting seminars and calls for funding and a lot more.